Comparing SYS6002 to Chemotherapy for Advanced Cervical Cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called SYS6002 against standard chemotherapy for cervical cancer that has come back or spread. It aims to see if SYS6002 works better for people who have already tried platinum chemo and immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have cervical cancer (squamous cell, HPV-related adenocarcinoma, or adenosquamous type) that cannot be cured with surgery or radiation.
- You must have received platinum-based chemotherapy along with an immunotherapy drug (like a PD-1 or PD-L1 inhibitor) before, and your cancer got worse during or within 6 months of finishing that treatment.
- You can have had no more than 2 prior treatments for advanced or recurrent cancer.
- You must have measurable tumors on scans (per RECIST guidelines).
- You must be in good general health (ECOG performance status 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called 9MW2821 against standard chemotherapy options for cervical cancer that has come back or spread. The goal is to see if the new drug works better than the usual treatments, and you must have already tried a platinum-based chemotherapy.
This trial tests a new drug called SYS6002 against standard chemotherapy for patients with advanced bladder cancer (urothelial carcinoma) that has already progressed despite previous treatments. The goal is to see if SYS6002 works better and is safer than chemotherapy.
This trial tests a new drug called SYS6010 against standard chemotherapy in people with advanced breast cancer that has a specific protein (EGFR) but not the HER2 protein. It is for those whose cancer has come back or spread and who have already had some chemotherapy.
This trial tests a new drug called SYS6010 against standard single-drug options in people with head and neck cancer that has returned or spread after prior treatment. The goal is to see if SYS6010 can shrink tumors or slow the disease better than the usual choices.
This study compares a new drug called SYS6010 with standard chemotherapy for advanced esophageal squamous cell carcinoma that has progressed after prior treatment. It may be an option if you have this specific type of esophageal cancer and are looking for a new treatment approach.
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.